HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Palliation of bone pain in patients with metastatic cancer using strontium-89 (Metastron).

Abstract
Bony metastasis is the most common cause of cancer pain. Strontium-89 (Sr-89), or Metastron, therapy has been shown to be effective for the palliation of pain due to skeletal metastases. By reducing opioid analgesics intake and restoring mobility, Sr-89 improves the patient's quality of life. Sr-89 is given conveniently as an outpatient procedure, and when necessary it can be repeated at 3-month intervals. Sr-89 is useful as an adjunct to local external beam radiation (EBR) because Sr-89 will target all skeletal metastases, including those not included in the EBR field. Because Sr-89 is a beta-emitting radionuclide with a long physical half-life (50.5 days), precautions should be taken by the caretaker(s) against Sr-89 contamination from the patient's blood or excretions, particularly if the patient is incontinent.
AuthorsM K Kan
JournalCancer nursing (Cancer Nurs) Vol. 18 Issue 4 Pg. 286-91 (Aug 1995) ISSN: 0162-220X [Print] United States
PMID7545083 (Publication Type: Journal Article, Review)
Chemical References
  • Strontium Radioisotopes
  • strontium chloride
  • Strontium
Topics
  • Bone Neoplasms (mortality, radiotherapy, secondary)
  • Clinical Trials as Topic
  • Humans
  • Palliative Care (methods)
  • Radiotherapy, Adjuvant
  • Strontium (adverse effects, therapeutic use)
  • Strontium Radioisotopes (adverse effects, therapeutic use)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: